Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Mental anguish from gynecomastia can last decades

Posted: July 23, 2014

Lorne Jaffe, a stay-at-home dad and blogger for the Huffington Post describes life with gynecomastia, a condition in which adolescent boys grow breasts, this way: “I grew up a seemingly normal, slightly chubby boy who by age 11 had a

Adherence to statin therapy linked to increased risk of type 2 diabetes

Posted: July 23, 2014

People who adhere to statin therapy to lower their cholesterol levels and reduce their risk for cardiovascular disease are at greater risk of developing new-onset type 2 diabetes, according to a study published in the journal Diabetes Care.

Controversial analysis suggests Actos may help protect users from dementia

Posted: July 22, 2014

The type 2 diabetes drug Actos could help ward off dementia, a new analysis has found. However, researcher say more analysis is needed as well as adverse side effects addressed before the medication can be recommended as a preventative measure.

Transvaginal mesh lawsuits continue three years after FDA warning

Posted: July 22, 2014

It has been three years since the Food and Drug Administration (FDA) issued a Safety Communication warning the public that complications with transvaginal mesh used to treat pelvic floor disorders including pelvic organ prolapse and stress urinary incontinence were not

Lipitor side effects lawsuits mounting against Pfizer

Posted: July 22, 2014

Lawsuits have been mounting against drugmaker Pfizer alleging the company failed to warn the public that its top selling cholesterol-lowering statin Lipitor could cause type 2 diabetes.

Hormonal contraceptives may increase risk of gestational diabetes

Posted: July 21, 2014

Women who use contraceptives that contain hormones before they become pregnant may be at greater risk for developing gestational diabetes once they do get pregnant, according to a new study.

Pre-diabetes diagnoses benefit drug companies more than patients

Posted: July 20, 2014

Non-diabetics with higher-than-recommended blood sugar levels and thus at risk for developing type 2 diabetes are considered pre-diabetic, however classifying large numbers of people with pre-diabetes offers more benefit to drug companies than those diagnosed with the condition, researchers argue.

New blood clot warning added to safety labels of testosterone replacement therapies

Posted: July 20, 2014

The safety labels of testosterone replacement treatments have been updated to include warnings of an increased risk of life threatening blood clots. The update comes on the heels of a Food and Drug Administration (FDA) safety alert notifying the public

Fresenius faces more lawsuits over generic drugs

Posted: July 20, 2014

Fresenius Kabi, one of four business segments of the worldwide dialysis service and product provider Fresenius Medical Care, is being accused by drugmaker Cubist Pharmaceuticals of infringing on four patents for the intravenous antibiotic Cubicin, used to treat skin and

FDA revokes approval for seven painkillers containing acetaminophen

Posted: July 19, 2014

The U.S. Food and Drug Administration (FDA) has revoked approval for seven narcotic painkillers containing acetaminophen, including versions of AbbVie Inc.’s Vicodin. The agency has done this in response to recent concerns about these drugs’ potential of causing liver damage.